Adverse events · adults
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether bovine colostrum changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · adults requiring an artificial airway with or without mechanical ventilator support
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults requiring an artificial airway with or without mechanical ventilator support
1 finding from 1 review
Adverse events · adults requiring an artificial airway with or without mechanical ventilator support
1 finding from 1 review
Adverse events · postmenopausal women with osteoporosis and CKD stages 5 and 5D
1 finding from 1 review
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: infection · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: other · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Grade 3 to 4 adverse events · Patients with COVID‐19
1 finding from 1 review
Serious adverse events · adults with renal vasculitis
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis
Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review